Epigral Limited, a leading chloro alkali manufacturer, announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company's Board of Directors approved the results at a meeting held on January 30, 2026, showing a challenging quarter with revenue and profitability pressures. The company has also fulfilled its regulatory obligations by publishing these results in Financial Express under Regulation 47 of SEBI listing requirements.

Financial Performance Overview

The company's operational performance reflected mixed trends across key metrics during the quarter:

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Epigral's performance showed year-over-year decline in key financial parameters:

Quarterly Performance Trends

The company's sequential performance showed improvement from the previous quarter:

Regulatory Compliance and Publication

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Epigral Limited published its unaudited financial results in Financial Express (English & Gujarati edition) on January 31, 2026. Company Secretary & Compliance Officer Gaurang Trivedi confirmed the newspaper publication to both NSE and BSE exchanges.

Consolidated vs Standalone Results

The consolidated financial results, which include associates ReNew Green (GJS Three) Private Limited and Pro-Zeal Green Power Ten Private Limited, showed minimal variance from standalone figures:

Business Operations and Market Position

Epigral operates primarily in the chloro alkali and its derivatives segment, with sales substantially in the domestic market. The company's business activities fall within a single reportable segment as per Indian Accounting Standards. The financial results demonstrate the company's continued focus on operational efficiency despite challenging market conditions in the chemical sector.

Epigral Limited has announced a conference call to discuss its Q3FY26 financial results, scheduled for Friday, January 30, 2026, at 5:00 PM IST. The company has formally notified both the National Stock Exchange of India Limited and BSE Limited about this upcoming investor interaction.

Regulatory Compliance and Notification

The company submitted the conference call intimation on January 23, 2026, in compliance with Regulation 30 and Para (A) of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Gaurang Trivedi (M. No. - A22307) signed the formal notification to the stock exchanges.

Management Participation

The Q3FY26 results discussion will feature key members of Epigral Limited's senior management team:

• Maulik Patel – Chairman and Managing Director
• Kaushal Soparkar – Executive Director
• Rakesh Agrawal – Chief Financial Officer
• Milind Kotecha – Investor Relations and Strategy

Conference Call Details

Emkay Global Financial Services Ltd is facilitating the conference call with comprehensive access arrangements for participants:

International Dial-in Access

The conference call provides extensive international toll-free access across multiple countries including Argentina, Australia, Belgium, Canada, China, France, Germany, Hong Kong, Italy, Japan, Netherlands, Poland, Singapore, South Korea, Sweden, Thailand, UK, and USA. Each country has dedicated toll-free numbers for seamless participation.

Contact Information

For additional information regarding the conference call, participants can contact Meet Vora at meet.vora@emkayglobal.com or call +91 22 6624 2474. The company encourages pre-registration to avoid wait times and enable express joining through the DiamondPass™ feature.